Cannabis is a lot more chemically complex than most people realize. It’s not just about THC or CBD. In fact, according to research from Stellenbosch University, the plant contains over 750 metabolites, and scientists are still finding compounds they’ve never seen before.
The latest discovery is particularly intriguing: a rare group of phenolic compounds called flavoalkaloids, identified in cannabis leaves for the first time. The research team analyzed three commercially grown strains from South Africa and found 79 phenolic compounds in total. Twenty-five of them had never been reported in cannabis before. Among these were 16 compounds tentatively classified as flavoalkaloids, which are extremely rare in nature.
This isn’t just academic trivia. These flavonoids and related compounds are already known in medicine for their antioxidant, anti-inflammatory, and anti-carcinogenic effects. The implication is clear: cannabis might have far more therapeutic potential than current research suggests, and we’re only scratching the surface of understanding why.
The Challenge of Finding Invisible Chemistry
The problem with studying plant phenolics is that they exist in frustratingly small amounts and have wildly diverse structures. Dr. Magriet Muller, the study’s first author and an analytical chemist at the university’s Central Analytical Facility, explains the difficulty plainly. “Most plants contain highly complex mixtures of phenolic compounds, and while flavonoids occur widely in the plant kingdom, the flavoalkaloids are very rare in nature,” she says.
Muller didn’t set out to revolutionize cannabis research. She’d been developing advanced analytical methods combining two-dimensional liquid chromatography with high-resolution mass spectrometry. She’d tested these tools on rooibos tea, grapes, and wine. Then she realized cannabis would be the perfect stress test for her methods because of its known chemical complexity.
The strategy worked. Prof. André de Villiers, who led the study, credits the advanced analytical approach. “The excellent performance of two-dimensional liquid chromatography allowed separation of the flavoalkaloids from the much more abundant flavonoids, which is why we were able to detect these rare compounds for the first time in cannabis,” he explains.
What’s particularly striking is that these flavoalkaloids weren’t evenly distributed across the three strains examined. They were concentrated mainly in the leaves of just one strain, suggesting that chemical variation between cannabis types is far greater than anyone anticipated. This variation opens new questions about why different strains produce different compounds and whether growers could theoretically cultivate specific phenolic profiles.
The Waste Problem Nobody Thought to Solve
Here’s where things get interesting from a practical standpoint. Most cannabis research has focused obsessively on cannabinoids, the compounds responsible for psychoactive effects. Everything else gets treated as secondary. But the leaves that are typically discarded as waste might contain exactly the compounds researchers are now interested in.
Prof. de Villiers argues this perspective misses an opportunity. “Our analysis again highlights the medicinal potential of cannabis plant material, currently regarded as waste. Cannabis exhibits a rich and unique non-cannabinoid phenolic profile, which could be relevant from a biomedical research perspective,” he says.
This research, published in the Journal of Chromatography A, suggests that the plant’s most underexploited medicinal value might literally be the parts we’ve been throwing away. It’s a reminder that even well-established plants can hold surprises when you have the right tools to look for them.
The real question now is whether the scientific community will follow up. Will researchers investigate whether these flavoalkaloids have the same therapeutic effects as their better-known cousins? Will growers start paying attention to cultivating strains rich in specific phenolics? Or will this discovery, like many others in cannabis science, get filed away while everyone waits for regulatory frameworks to catch up?
